Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 96Stomach Neoplasms 53Rectal Neoplasms 49Pancreatic Neoplasms 42Colonic Neoplasms 34Esophageal Neoplasms 30Neoplasm Metastasis 28Neoplasms 23Adenocarcinoma Of Esophagus 19Adenocarcinoma 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Lymphoma, Large B-Cell, Diffuse 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Esophageal Squamous Cell Carcinoma 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Liver Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Recurrence 4Lymphoma, Non-Hodgkin 4Gastrointestinal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Bile Duct Neoplasms 4Peritoneal Neoplasms 3Pancreatic Adenocarcinoma 3Leukemia 3Fallopian Tube Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1cabozantinib 1andecaliximab 1Trifluridine 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Irinotecan 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastric Adenocarcinoma × Oxaliplatin × Clear all
NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡